Biocon jumps as its arm inks pact with Sandoz

26 Dec 2023 Evaluate

Biocon is currently trading at Rs. 249.75, up by 3.55 points or 1.44% from its previous closing of Rs. 246.20 on the BSE.

The scrip opened at Rs. 247.65 and has touched a high and low of Rs. 252.05 and Rs. 247.65 respectively. So far 77793 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 279.95 on 15-Sep-2023 and a 52 week low of Rs. 191.60 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 257.65 and Rs. 239.45 respectively. The current market cap of the company is Rs. 30051.02 crore.

The promoters holding in the company stood at 60.64%, while Institutions and Non-Institutions held 22.05% and 17.32% respectively.

Biocon’s subsidiary -- Biocon Biologics (BBL) has signed a Distribution Agreement with Sandoz, granting the Company the exclusive rights to promote, sell and distribute ‘Adalimumab BS for subcutaneous injection [FKB]’ in Japan. Based on this Agreement, Viatris has completed marketing and promotion of the product as of December 15, 2023, but will continue to provide transition support until Sandoz will gradually assume responsibilities for the product starting February 15, 2024.

Biocon Biologics has acquired the global biosimilars portfolio of Viatris including Adalimumab. Fujifilm Kyowa Kirin Biologics Co., the developer of the drug, has concluded an exclusive global marketing license agreement with Biocon Biologics affiliate.

Adalimumab BS for subcutaneous injection [FKB] is a biosimilar of Humira (generic name: adalimumab (genetical recombination)) and is indicated for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn's disease, and ulcerative colitis. 

Sandoz is committed to further strengthening its product pipeline to drive sustainable business growth. The transfer of the distribution rights of this product is part of this strategy, and its addition to the product portfolio will strengthen Sandoz's immunology and biosimilar portfolio.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

307.00 15.30 (5.25%)
26-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1504.25
Dr. Reddys Lab 6263.70
Cipla 1406.25
Zydus Lifesciences 948.20
Lupin 1615.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.